Vor Biopharma INC

Vor Biopharma Inc. reports the resignation of Director Andrew Levin and the appointment of David Zaccardelli to its Board.

Vor Biopharma stockholders approved an amended 2021 Equity Incentive Plan and elected two directors at the 2026 Annual Meeting.

Vor Biopharma announces NMPA conditional approval for IgA nephropathy and approval for Sjögren's disease for telitacicept in China, developed by collaborator RemeGen.

Vor Bio announced a $75 million private placement led by TCGX to accelerate clinical development of telitacicept for autoimmune diseases.

Vor Biopharma Inc. announced preliminary cash of $450 million for year-end 2025 and provided updates on its telitacicept autoimmune programs, including global Phase 3 trials for Myasthenia Gravis and Sjögren's Disease.

VOR Biopharma Inc. announced the departure of its Chief Development Officer, Dr. Qing Zuraw, effective December 31, 2025, with a separation agreement detailing severance and a 12-month non-compete.

Vor Biopharma Inc. filed its Form 10-Q for the quarter ended March 31, 2026, detailing its financial condition, results of operations, and cash flows, with a significant focus on the development of its lead product candidate, telitacicept.

Vor Biopharma reported a significant net loss of $2.4 billion for the nine months ended September 30, 2025, driven by a non-cash warrant revaluation and a strategic pivot to its newly in-licensed autoimmune drug, telitacicept.

Vor Biopharma Inc. reports a significant strategic shift to autoimmune diseases with the in-licensing of telitacicept, alongside a major restructuring and leadership overhaul, despite a substantial net loss driven by warrant revaluation.

Vor Biopharma is halting its clinical and manufacturing operations to explore strategic options for maximizing shareholder value.

Vor Biopharma announced its third quarter 2024 financial results, provided updates on its clinical trials for trem-cel and VCAR33 ALLO, and appointed a new Chief Financial Officer.

Vor Biopharma filed an amendment to its quarterly report to disclose a Rule 10b5-1 trading plan adopted by its Chief Medical Officer.

Vor Biopharma refocused on autoimmune drug telitacicept, advanced two global Phase 3 trials, reported a $696.0M 2025 net loss driven by a $222.6M license charge and warrant revaluation, and announced a $75.0M private placement to extend cash runway into early 2029.

Vor Biopharma's 2024 10-K filing details the company's ongoing clinical trials, preclinical programs, and financial position, emphasizing its cell and genome engineering approach to treating AML.

Vor Biopharma, a clinical-stage company, provided an update on its financial results for 2023 and progress in its clinical programs, including trem-cel and VCAR33 ALLO.

Ra Capital Management, L.P. and 3 others reported changes in beneficial ownership of Vor Biopharma Inc. common stock on July 16, 2026.

Vor Biopharma Inc. reports that Director David Zaccardelli was granted stock options for 42,658 shares.

RA Capital Management reports the acquisition of stock options by Dr. Andrew Levin on behalf of the investment fund.

Director Michel Detheux was granted 57,162 stock options in Vor Biopharma Inc. as part of standard equity compensation.

Director Fouad Namouni was granted 56,549 stock options in Vor Biopharma Inc. as part of a standard equity compensation arrangement.

Director Wouter Joustra was granted 57,162 stock options in Vor Biopharma Inc. as part of a standard equity compensation plan.

Vor Biopharma Inc. announced its 2026 Annual Meeting of Stockholders will be held virtually on June 11, 2026, with key proposals including director elections and equity plan amendments.

Vor Biopharma Inc. calls a special meeting to approve a reverse stock split, the issuance of over 1 billion shares from warrants, and an expanded equity incentive plan.

Vor Biopharma is holding its annual meeting on May 22, 2025, to vote on director elections, an increase in authorized common stock, and ratification of its accounting firm.

Vor Biopharma Inc. is holding its annual meeting on May 22, 2025, to elect directors, approve an increase in authorized shares, and ratify the selection of Ernst & Young LLP as the independent auditor.

Vor Biopharma is holding its 2025 Annual Meeting of Stockholders virtually on May 22, 2025, to vote on key proposals including increasing authorized common stock, electing directors, and ratifying the selection of Ernst & Young LLP as the independent auditor.

Vor Biopharma announces the appointment of Fouad Namouni, M.D., to its Board of Directors, increasing the board size to seven members.

RA Capital Management, L.P. and its affiliates have amended their Schedule 13D filing to report changes in beneficial ownership of VOR BIOPHARMA INC. common stock.

RA Capital Management reports a reduction in its beneficial ownership of Vor Biopharma Inc. common stock following recent open market sales.

RA Capital Management has disclosed a reduction in its beneficial ownership of VOR Biopharma Inc. following a series of open market sales.

RA Capital Management and its affiliates have filed an amendment to their Schedule 13D, reporting a decrease in their beneficial ownership of VOR Biopharma Inc. common stock to 19.9%.

RA Capital Management and its affiliates have filed an amendment to their Schedule 13D, reporting a beneficial ownership of 19.9% in VOR Biopharma Inc. following recent stock sales.

RA Capital Management, L.P. and its affiliates filed an Amendment No. 13 to their Schedule 13D, reporting a beneficial ownership of 19.9% in VOR Biopharma Inc. due to an increase in outstanding shares.

Venrock Healthcare Capital Partners reports a 9.9% beneficial ownership stake in Vor Biopharma Inc. as of March 31, 2026.

Verve Capital Limited has filed an amendment to its Schedule 13G, reporting a 9.3% beneficial ownership stake in Vor Biopharma Inc.

Qiming Venture Partners entities report beneficial ownership of over 5% of VOR BIOPHARMA INC. common stock as of March 31, 2026.

FMR LLC and Abigail P. Johnson have jointly filed a Schedule 13G, reporting beneficial ownership of 1,539,670 shares of VOR BIOPHARMA INC common stock, representing 3.2% of the class.

TCG Crossover Funds and Chen Yu disclose significant beneficial ownership in Vor Biopharma Inc., reaching 10.5% for Chen Yu following a recent offering.

Qiming Venture Partners entities disclose an updated passive ownership stake in VOR Biopharma Inc., holding a combined beneficial interest of approximately 5.17%.